BCL2 and breast carcinoma: Mocetinostat combined with capecitabine showed a synergistic effect on suppression of proliferation and induction of apoptosis in 4T1 breast cancer cells via targeting Bax, Bcl-2, PI3K/AKT, c-Myc, PTEN, p53, caspase-7, -9, and cleaved PARP (89).